Cytori Therapeutics Inc. (CYTX) Trading Up 3.1%
Cytori Therapeutics Inc. (NASDAQ:CYTX) was up 3.1% on Friday . The company traded as high as $2.04 and last traded at $2.02, with a volume of 69,700 shares traded. The stock had previously closed at $1.96.
A number of equities research analysts recently weighed in on CYTX shares. Maxim Group restated a “buy” rating and set a $75.00 price objective on shares of Cytori Therapeutics in a research note on Thursday, March 24th. Roth Capital began coverage on Cytori Therapeutics in a research report on Monday, March 28th. They set a “buy” rating and a $22.50 target price on the stock. Finally, Zacks Investment Research lowered Cytori Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 4th.
The stock’s 50-day moving average is $2.19 and its 200 day moving average is $2.87. The firm’s market cap is $27.00 million.
Cytori Therapeutics (NASDAQ:CYTX) last released its earnings results on Tuesday, May 10th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.03) by $0.38. During the same period in the previous year, the business posted ($0.07) EPS. The company earned $2.90 million during the quarter, compared to analysts’ expectations of $2.05 million. The company’s revenue for the quarter was up 26.1% compared to the same quarter last year. On average, equities research analysts predict that Cytori Therapeutics Inc. will post ($1.59) earnings per share for the current fiscal year.
Cytori Therapeutics, Inc (Cytori) is a biotechnology company involved in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company is engaged in developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns combined with radiation injury.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.